Why Dutch Doctors Pulled the Plug on a Viagra Pregnancy Study
It’s a tale of hope, heartbreak, and a little medical cautionary tale that turns a Viagra‑style story into something far more dramatic than any typical pharmacy ad.
What the Study Was About
- Researchers at Amsterdam University Medical Centre (AUMC) teamed up with 10 other Dutch hospitals.
- They launched a trial in 2015 that aimed to help babies whose growth in the womb was lagging behind.
- The idea? Viagra (sildenafil) is a blood‑vessel dilator, so maybe it could push more oxygen and nutrients to the placenta.
The Stakes (and the Stakes That Went Wrong)
When the study stopped last week, the numbers were a sobering set of statistics:
- 93 women took Viagra. Out of their babies, 19 died.
- 11 of those deaths may have been linked to a high‑blood‑pressure‑in‑the‑lungs condition.
- There were also 6 babies who survived but were born with a lung condition that left them gas‑hungry.
- 90 women received a placebo. Out of those babies, 9 died, none from lung problems.
- Three of the placebo babies also had lung issues.
- Now, 10‑15 women are waiting to see if the medication has worsened their unborn child.
Why It Was Halted
Dr. Wessel Ganzevoort, the study’s lead, reflected on the shock:
“We thought we were about to make a breakthrough that could give babies the growth boost they desperately need. Trust us, that’s why we saw Viagra as a promising option. The opposite happened, and that’s the last thing any medical team wants.”
The team also shared the findings with Canadian researchers who were running similar trials.
What This Means for Tomorrow
Although the idea of using a familiar erectile‑dysfunction medicine to improve fetal growth sounded incredibly clever, the data tell a different story. A study that could have helped dozens of pregnant women ended up contributing to tragically unintended outcomes.
So the takeaway? When life‑saving treatments are still landing in the lab, especially when babies are at stake, a little extra caution can’t be overstated.
